Drugs / Subcutaneous immunotherapy (SCIT)
last change Feb 2017 re-read 2 minutes ago

Subcutaneous immunotherapy (SCIT)

Other / unclassified

Developed for
seasonal allergic rhinitis
Investigated by
Immune Tolerance Network (ITN) · Imperial College London · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01335139 Mar 2011 → Feb 2015 seasonal allergic rhinitis National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Subcutaneous immunotherapy (SCIT) ClinicalTrials.gov intervention name — accepted as the source's own label NCT01335139
Modality Other / unclassified “subcutaneous injection immunotherapy” NCT01335139
Route Subcutaneous subcutaneous immunotherapy (monthly injections containing 20 µg of Phleum p 5)” PMID 28196255 Feb 2017